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The present article will show the various manifestations of the disease and discusses the diagnosis, clinically as well as genetically, and treatment options.
Case report 1.
The first patient is a previously healthy 18-year-old woman and competitive endurance sports athlete, who died suddenly during a running contest. Autopsy revealed a mildly hypertrophic and dilated left ventricle compatible with the effects of endurance sports activities. There were no coronary artery or valvular abnormalities. The right ventricle was markedly dilated and there was a striking transmural fatty degeneration No other abnormalities were found.
Histologic examination proved right ventricular cardiomyopathy .In combination with the sudden cardiac death, Arrhythmogenic right ventricular cardiomyopathy is present.
Case report 2.
Patient B is a 31-year-old woman and one of the two sisters of the previous patient. She has no medical history and is also a competitive endurance athlete. At age 18, after the sudden death of her sister, she undergoes cardiac evaluation which appears completely normal, including a normal electrocardiogram and two dimensional echocardiogram. However 13 years later she is referred again to the cardiologist having dyspnea on exertion. Careful his- tory analysis reveals that this 'dyspnea' was due to the occurrence of paroxysms of palpitations which she doesn't feel during her endurance contests. During that visit she also mentioned that her father died suddenly three years before at age 65. There are no risk factors for coronary artery disease. On physical examination a healthy, trained woman was seen.
Her blood pressure was 120/70 mm Hg and her pulse rate 60 per minute regular and equal.
An early systolic ejection murmur was heard at the 4th left intercostal space but remaining physical examination was normal. This time the electrocardiogram showed a sinusbradycardia and inverted T-waves in precordial leads V1 till V 3. (Figure 1 ) Chest X-ray and echocardiogram were normal. During exercise testing the electrocardiogram showed short runs of ventricular complexes which had a left bundle branch block morphology with superior axis. (Figure 2 ) This morphology corresponds with an origin of ectopy inferiorly in the right ventricle. Holter monitoring disclosed more than 1000 ventricular complexes per 24 hour. She was advised to avoid peak exercise and a beta blocking agent was prescribed. After that, only solitary ventricular premature complexes were noted on the exercise test.
Subsequently a MRI showed a diffuse thinning of the right ventricular wall. After the initiation of the beta blocker she developed symptomatic bradycardia and electro- physiological testing was performed during which ventricular fibrillation could easily be induced. Meanwhile, echocardiography of the right ventricle showed mild dilatation and apical hypo-and akinesia. After this an implantable cardioverter defibrillator (ICD) was implanted and she was treated with the beta-blocking agent Sotalol. No ICD discharges or arrhythmic events have been reported so far. Four years after the implantation, she leads a normal life, participates in non competitive sports regularly and has fulfilled two uncomplicated pregnancies.
Genetic analysis
After the recent identification of the Plakophilin-2 (PKP2) gene mutation as a causal gene mutation for ARVC 4, we analyzed this patient for the presence of PKP2 mutations. Genomic DNA was isolated from peripheral blood lymphocytes (Gentra Systems, Minneapolis, USA) and the entire PKP2 coding region was screened for mutations. Primer sequences and PCR conditions are available on request. Mutational analysis of the amplimers was performed by DHPLC (Transgenomic). PCR products with altered DHPLC peaks were purified using QIAquick PCR purification kit (Qiagen, Hilden, Germany) and were sequenced bidirectionally on an ABI 377 sequencer. In patient 2 at base position 2421 a Cytosine (C) was replaced by an Adenine (A) causing a premature termination codon at position 807 (Tyrosine 807X)( Figure 4 ). It is highly likely that this alteration underlies her clinical phenotype. A third sister was also genetically tested and appeared not to have the PKP2 mutation.
Discussion
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) was initially defined as 'total or partial replacement of right ventricular muscle by adipose and fibrous tissue associated with arrhythmias of left bundle branch block configuration'. 1, 2 The typical anatomic findings are aneurysmatic regions due to myocardial thinning. In these regions the myocardial wall is replaced by fibro-fatty tissue with scattered residual myocardial bundles, a perfect substrate for arrhythmias.
Specific sites of involvement include the right ventricular outflow tract, the apex, and the infundibular region, the so-called 'triangle of dysplasia'. ( Figure 4 ) The fibrofatty tissue replacement can also affect the left ventricular myocardium with a relative sparing of the septum. 5,6,7 These sites form an excellent substrate for re-entry which can lead to arrhythmias such as premature ventricular complexes, ventricular tachycardia and ventricular fibrillation. Because of the predominant origin in the right ventricle these arrhythmias have, frequently but exclusively, a left bundle branch block morphology (Figure 2 ).
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The prevalence of ARVC in the general population is estimated at 0.02 to 0.1%, but this may be underestimated because of diagnostic difficulties and physicians being unaware of this disease. 5 Both sexes are equally affected and there is a peak of risk of developing the disease during the fourth decade. 5 ARVC is an important cause of sudden death in young adults accounting for approximately 11 percent of the cases. In athletes, such as the women described in this article, ARVC counts for 22 percent of the sudden death cases. 8 Although this suggests that exercise is a risk, sudden death occurs most frequently during sedentary activity. 6 The definite diagnosis of ARVC is based on the histological demonstration of transmural fi- is based on a number of major and minor criteria involving structural, histological, electrocardiographic, arrhythmic and genetic factors. 10 To fulfil the appropriate criteria for ARVC, patients have to meet either two major criteria, one major and two minor criteria, or four minor criteria ( Table 1) .
The patient in case report 1 died suddenly and the diagnosis was made by autopsy. At that time, patient 2 fulfilled only one major criterion consisting of her sisters proven ARVC.
Hence the diagnosis could not be made. During the second evaluation this second sister also had repolarization abnormalities on her ECG (minor, Figure 1 ), arrhythmias on exercise The diagnosis of ARVC would be fulfilled by the presence of 2 major, 1 major plus 2 minor, or 4 minor criteria from different groups. 277 13 test ( Figure 2) and Holter (minor), and later also localized right ventricular akinesia on echo (major) along with late potentials during electrophysiological testing (minor). Genetic analysis revealed a mutation in the PKP2 gene which is, at present, not a diagnostic criterion, but confirms the diagnosis.
A third sister had the major criterion consisting of the death of her sister with proven ARVC but otherwise no clinical abnormalities and was screened negative for the PKP2 mutation. ARVC is found to be familial in 30 to 50% of the cases. 11 It is usually inherited in an autosomal dominant manner with reduced and age-related penetrance 11 , but autosomal recessive forms have been reported. Several genetic loci have been reported to be associated with the disease and mutations in 6 genes have been identified: ryanodine receptor, plakoglobin, desmoplakin and recently transforming growth factor-β, plakophilin-2. and desmoglein 12, 13, 14, 15, 16, 17, 18, 19 Patients with mutations in the ryanodine receptor gene , also called ARVC2, are more prone to develop arrhythmias. 20 The recognition that ARVC is frequently familial and can cause arrhythmic death leads to the challenge to identify family members who are at risk. Difficulties arise in diagnosing the presymptomatic subjects because identification of minimal structural abnormalities is difficult because of the irregular shape and asymmetrical contractile pattern of the right ventricle. Even on Magnetic Resonance Imaging (MRI) the diagnosis of ARVC cannot be made on the presence of intramyocardial fat or wall thinning alone. A study from Bomma demonstrated a high frequency of misdiagnosis of ARVC on MRI. 21 Asymptomatic ARVC patients should have an annual follow-up and currently there is no current evidence for medical treatment is this group. However, competitive exercise should be avoided. Patients who presented with well tolerated and non-life threatening ventricular tachycardia can be treated conservatively with anti-arrhythmic drugs, guided by Holter monitoring and exercise testing and, in selected cases, by programmed electrical stimulation. The most effective drug used in treating ARVC patients with non-life threatening ventricular tachycardia is Sotalol with an efficacy rate of 68% followed by Amiodarone with a efficacy rate of 15%. 22 Radiofrequency ablation is an alternative in this group of patients who are unresponsive or intolerant to anti-arrthythmic drugs. 23, 24 Patients who have been resuscitated or who have had a hemodynamically unstable ventricular tachycardia like the patient in case report 2, should be treated with an Implantable Cardioverter-Defibrillator. 25 Prophylactic ICD implantation will becoming more important in certain families depending on the aggressiveness of their gene mutation. In these families genetic screening would constitute an important tool in diagnosing persons at risk for this potentially life-threatening disorder.
Conclusion
The two previous described cases illustrate the wide variety in clinical presentation of Arrhythmogenic Right Ventricular Cardiomyopathy.
The clinical manifestations of ARVC are various and age dependent. Therefore the diagnosis of this illness can be difficult. For every physician, not only cardiologists but also general physicians, internists and sport physicians, it is important to be aware of this disease when a patient presents with syncope or palpitations, especially when there is a family history of sudden death. Because of the major implications and the prevention of sudden death, it is recommended to screen both clinically and genetically family members of known ARVC patients. In the near future, genetic testing will probably provide the gold standard for diagnosis. 26 Literature
